21 completed, 10 terminated, 8 unknown, 2 not yet recruiting. 13 Phase 2, 13 Phase 3, 8 Not applicable, 6 Phase 1, 6 Phase 4.
Follow fosaprepitant: new trials by email Literature Review of fosaprepitant trials Research Report on fosaprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide Fosaprepitant for Injection, Metoclopramide Injection - Nausea and Vomiting, Nausea | Phase 4 | Not yet recruiting | Montefiore Medical Center | 212 | 2026-12-01 | 2026-06-29 |
| Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen Fosaprepitant, Tropisetron, Olanzapine - Multiple Myeloma | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 92 | 2025-10-31 | 2026-02-17 |
| To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. QLM2010 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone - Chemotherapy-Induced Nausea and Vomiting | Phase 3 | Completed | Qilu Pharmaceutical Co., Ltd. | 665 | 2025-01-03 | 2025-11-18 |
| Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Fosaprepitant 150 mg, Ondansetron 4 mg - Nausea and Vomiting, Nausea | Phase 2 / Phase 3 | Recruiting | Montefiore Medical Center | 200 | 2024-11-13 | 2026-05-18 |
| An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects BH006 for injection, Fosaprepitant for injection+Palonosetron hydrochloride injection - Bioavailability | Early Phase 1 | Unknown | Zhuhai Beihai Biotech Co., Ltd | 40 | 2024-05-01 | 2024-05-24 |
| Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention fosaprepitant, normal saline - Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures | Not applicable | Enrolling by invitation | Samsung Medical Center | 144 | 2023-08-18 | 2025-03-30 |
| Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer Aprepitant, Palonosetron, Fosaprepitant - Breast Cancer, Chemotherapy-induced Nausea and Vomiting | Phase 4 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 1028 | 2023-07-01 | 2023-05-03 |
| Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic Surgery Ondansetron 8mg, Fosaprepitant 150 mg - Postoperative Nausea and Vomiting, Anesthesia Complication | Not applicable | Unknown | Qilu Hospital of Shandong University | 234 | 2023-06-01 | 2023-06-06 |
| Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors HR20013 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone - Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy | Phase 3 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 754 | 2022-09-21 | 2023-10-27 |
| Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients Fosaprepitant,ondansetron, dexamethasone, placebo ondansetron with dexamethasone - Pediatric Cancer | Phase 2 | Completed | Sun Yat-sen University | 108 | 2022-08-01 | 2024-01-09 |
| Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV. Fosaprepitant Dimeglumine for Injection - Neoplasms | Not applicable | Unknown | Xijing Hospital | 3000 | 2022-07-15 | 2023-03-06 |
| Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs Fosaprepitant, Placebo(normal saline) - Chemotherapy Induced Nausea and Vomiting Pediatric Cancer Patients | Not applicable | Unknown | Shanghai Children's Medical Center | 120 | 2022-02-01 | 2022-02-09 |
| Anti-emetic Prophylaxis With or Without Dexamethasone Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen, Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | Henan Cancer Hospital | 442 | 2022-02-01 | 2024-10-10 |
| Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury Fosaprepitant - Traumatic Brain Injury | Early Phase 1 | Withdrawn | Arun Gupta | 2021-11-01 | 2022-11-03 | |
| Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer Fosaprepitant, tropisetron, Dexamethasone - Cervical Cancer, Nasopharyngeal Cancer | Phase 3 | Completed | Shantou University Medical College | 116 | 2021-07-01 | 2024-02-06 |
| Granisetron Transdermal Patch for Prophylaxis of Delayed CINV Granisetron transdermal patch, Palonosetron, Aprepitant - Chemotherapy-induced Nausea and Vomiting (CINV) | Phase 3 | Unknown | Fudan University | 140 | 2021-06-10 | 2021-06-03 |
| Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients fosaprepitant, aprepitant, Granisetron plus dexamethasone - Chemotherapy Induced Nausea and Vomiting, Pediatric Cancer Patients | Not applicable | Unknown | Shanghai Children's Medical Center | 120 | 2021-05-01 | 2021-05-10 |
| Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA) - Gynecologic Cancer | Phase 3 | Terminated | University of Michigan Rogel Cancer Center | 62 | 2020-12-28 | 2025-06-18 |
| Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma fosaprepitant - Nasopharyngeal Carcinoma | Phase 1 | Completed | Sun Yat-sen University | 100 | 2020-11-24 | 2022-11-07 |
| Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 4 | Completed | Merck Sharp & Dohme LLC | 103 | 2019-09-09 | 2025-01-16 |
Showing 20 of 45. Sign in to see all of them.
Vomiting (27) · Nausea (10) · Neoplasms (5) · Postoperative Nausea and Vomiting (4) · Breast Neoplasms (2) · Multiple Myeloma (2) · Signs and Symptoms, Digestive (2) · Brain Injuries, Traumatic (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Genital Neoplasms, Female (1) · Melanoma (1) · Nasopharyngeal Carcinoma (1)
Merck Sharp & Dohme LLC (7) · M.D. Anderson Cancer Center (2) · Montefiore Medical Center (2) · Shanghai Children's Medical Center (2) · Sun Yat-sen University (2) · Acacia Pharma Ltd (1) · Ajeet Gajra (1) · Albert Einstein College of Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Arun Gupta (1) · Fudan University (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Gynecologic Oncology Associates (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Henan Cancer Hospital (1)
United States (19) · China (11) · Denmark (2) · Australia (1) · Brazil (1) · Germany (1) · Greece (1) · Guam (1) · Hungary (1) · Japan (1) · Lithuania (1) · Netherlands (1) · Norway (1) · Peru (1) · Poland (1)
Agustin Garcia (1) · Aimee Rolston (1) · Ajeet Gajra, MD FACP (1) · Arun Gupta, MD PhD (1) · Benjamin Friedman, MD (1) · Benjamin W Friedman, MD MS (1) · Christina Ruhlmann, MD (1) · Chuangzhen Chen (1) · Dorothy Keefe, MD, FRACP (1) · Felix Hilpert, MD, DMSci (1) · Gunnar Kristensen, MD, PhD (1) · Henrik Roed, MD, DMSci (1) · Hong Liu (1) · Hong Zhang, PI (1)
PMID 22739139, PMID 25770814, PMID 26449391, PMID 26838019, PMID 26952945, PMID 26997579, PMID 29808377, PMID 30488222, PMID 30900392, PMID 32988373, PMID 33023948, PMID 37284847, PMID 37498596, PMID 37851143, PMID 38323173, PMID 39621965, PMID 39655741, PMID 41520166, PMID 41836527
2009 (1), 2014 (1), 2018 (1), P30CA022453 (1), P30CA069533 (1), UG1CA189823 (1)